Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
Braz. j. infect. dis
;
24(4): 352-355, Jul.-Aug. 2020. tab, graf
Artículo
en Inglés
| LILACS, ColecionaSUS
| ID: biblio-1132468
ABSTRACT
Abstract Rifampicin is a key component of treatment for tuberculosis and its efficacy is determined by the blood levels attained after therapeutic doses. However, there is a high variability of rifampicin blood levels that is related to both the patient and the formulation used. To date, the effect of diabetes mellitus on the plasma levels of rifampicin was low exploited, which could be relevant either by the significant increase of the comorbidity worldwide as by the probable influence of diabetes on the rifampicin exposure. The study aims to evaluate whether diabetes mellitus contribute to the variation of the maximum concentration of rifampicin in patients with tuberculosis treated with a daily dose of 10 mg/kg. Rifampicin and glycated hemoglobin were measured by high-performance liquid chromatography, and blood glucose by spectrophotometry. A total of 62 male patients were included in the study, and 26 presented diabetes mellitus. Rifampicin plasma levels in 2-h plasma samples collected at day 61 ranged from 3 µg/mL to 14.2 µg/mL. Drugs levels were similar between diabetic and non-diabetic patients and were not correlated with blood glucose and glycated hemoglobin. Moreover, a high percentage of patients in both groups presented low levels of rifampicin.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Rifampin
/
Tuberculosis
/
Diabetes Mellitus
/
Antibióticos Antituberculosos
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Año:
2020
Tipo del documento:
Artículo
Institución/País de afiliación:
Universidade Federal do Pará/BR
Similares
MEDLINE
...
LILACS
LIS